A small molecule called NK036 — which inhibits USP30, an enzyme that counters the removal of damaged mitochondria from nerve cells in Parkinson’s disease — fits tightly into its target, suggesting it may have a strong and lasting effect as a treatment for the neurological condition, a new study…
The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program, which trains specialists in improving access to Parkinson’s disease care. The program provides funding each year for medical centers to train physicians to become Parkinson’s specialists.
The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s. RNA editing…
An experimental compound has been identified that shows the potential to reduce brain inflammation in neurodegenerative conditions such as Parkinson’s disease. MFP-0012328 works by blocking FABP4, a protein that researchers have shown to be key in the inflammatory activity of microglia, the brain’s immune cells. While other FABP4…
Switching actions and stopping movements involve two distinct cognitive motor processes, according to a study that combined computer modeling with tasks performed by healthy people. The findings have implications for people with Parkinson’s disease, who experience longer reaction times and delays when they want to start, stop, or switch…
Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS Parkinson’s symposium hosted last month by the University of Arkansas for Medical Sciences (UAMS), where the latest advances in diagnosing and treating people with Parkinson’s disease and atypical parkinsonism…
A $50,000 grant will allow Stockton University to provide free SPEAK OUT! voice therapy to people in New Jersey with Parkinson’s disease. Parkinson Voice Project (PVP), which is providing the grant, designed the SPEAK OUT! program to help Parkinson’s patients with motor symptoms including low speech volume, slurred…
Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434)…
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the…
Listening to rhythm-based cues while walking not only builds lasting walking habits, but also helps people with Parkinson’s disease walk more, at a greater intensity, and more steadily than walking on their own. These are the findings of a clinical study (NCT05421624) that tested MR-005, a digital tool…
Get regular updates to your inbox.
